About the Company
Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACOR News
Acorda Therapeutics Announces Delisting from Nasdaq
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down ...
Riskiest Junk Bonds Shunned In Europe On Rising Risk Of Default
The junkiest corporate debt is becoming increasingly hazardous for investors amid mounting signs that a default cycle is ...
Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. (Fed. Cir. 2024)
Norwich Pharmaceuticals Inc. The majority opinion raises issues in its invalidity analysis regarding the extent to which the prior art should be required to disclose the recited administered dose to ...
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a ...
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Multiple Sclerosis Drugs Market Forecasted to Reach USD 41 Billion by 2032: Unveiling Growth Prospects
According to a recent report by Market.us, the Global Multiple Sclerosis Drugs Market size is expected to be worth around USD 41 Billion by 2032 from USD 29.3 Billion in 2023, growing at a CAGR of 3.8 ...
Phase III win for Intra-Cellular's Caplyta for major depressive disorder
Robust top-line phase III data showed Intra-Cellular Therapies Inc.’s marketed oral atypical antipsychotic drug, Caplyta (lumateperone), achieved statistically significant and clinically meaningful ...
Loading the latest forecasts...